A Phase 2a clinical trial has finished testing the experimental therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF), according to its developer, Endeavor BioMedicines. Endeavor did not include in its announcement any specific data from the trial, but John Hood, PhD, the company’s co-founder, CEO, and…
News
Bersiporocin, an oral therapy for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 2 clinical trial, has been granted orphan drug status in Europe by the European Medicines Agency (EMA). The EMA gives this designation to treatments that have the potential to improve care for people with…
For the 14th year, a cast of Broadway luminaries will take the stage for the Pulmonary Fibrosis Foundation’s (PFF) largest fundraiser, Broadway Belts for PFF! The March 18 gala, which may also be viewed virtually, will raise funds and awareness for the more than 250,000 U.S. residents thought to…
The U.S. Food and Drug Administration (FDA) has approved Fibresolve, an AI or artificial intelligence-based software that’s designed to help — noninvasively — in the diagnosis of idiopathic pulmonary fibrosis (IPF) and other lung diseases marked by fibrosis, or scar tissue buildup. This marks the first FDA clearance of…
Almee, an investigational app that offers personalized treatment to help people with pulmonary fibrosis (PF), was found to significantly reduce anxiety levels in PF patients who participated in a pivotal randomized study. Positive results from the COMPANION (NCT05330312) study were announced by Alex Therapeutics and Vicore…
Berberine, a naturally occurring plant compound, eased the signs and symptoms of pulmonary fibrosis (PF) in a mouse model where the disease was triggered by exposing animals to fine particulate matter found in air pollution. The findings “offer novel insights into the mechanisms underlying the beneficial effects of…
A Phase 2a trial is recruiting people with idiopathic pulmonary fibrosis (IPF) to assess the effectiveness of GRI-0621, GRI Bio‘s investigational natural killer T-cell (NKT)-targeted therapy. The multicenter biomarker study, which was cleared to start by the U.S. Food and Drug Administration, is expected to have early results…
Trevi Therapeutics has launched a Phase 2b clinical trial testing therapeutic candidate Haduvio (nalbuphine extended-release tablets) for the treatment of chronic cough in people with idiopathic pulmonary fibrosis (IPF). The Phase 2b trial, CORAL (NCT05964335), plans to enroll about 160 adults with IPF and chronic cough. No…
The U.S. Food and Drug Administration (FDA) has given GRI Bio the green light to conduct a Phase 2 trial of its investigational natural killer T-cell (NKT)-targeted therapy, GRI-0621, in people with idiopathic pulmonary fibrosis (IPF). With the clearance of its investigational new drug (IND) application, the company…
Certain immune cells called natural killer (NK) T-cells are present at higher numbers in the lungs of people with idiopathic pulmonary fibrosis (IPF) than in the lungs of healthy people, according to data announced by GRI Bio. Also, the more NK T-cells, the greater the number of macrophages,…
